Basic Information
| LncRNA/CircRNA Name | TATDN1 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, Luciferase reporter assay |
| Sample | L02 cell line, HCC cell lines (PLC/PRF/5, Bel-7404, HepG2 and SMMC7721), HCC tissues and normal tissues |
| Expression Pattern | up-regulated |
| Function Description | TATDN1 was upregulated in HCC tissues and cell lines. The overexpression of TATDN1 accelerated the proliferative rate and cell cycle progression of HCC. MiRNA-6089, the target gene of TATDN1, was lowly expressed in HCC. The overexpression of miRNA-6089 partially reversed the promotive role of TATDN1 in regulating the proliferation and cell cycle of HCC cells. Subsequently, LIX1L was verified to be the target of miRNA-6089. The overexpression of LIX1L partially reversed the regulatory effect of miRNA-6089 on the proliferative rate and cell cycle progression of HCC. |
| Pubmed ID | 31378885 |
| Year | 2019 |
| Title | LncRNA TATDN1 induces the progression of hepatocellular carcinoma via targeting miRNA-6089 |
External Links
| Links for TATDN1 | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |